Systemic amyloidoses and proteomics: The state of the art

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalEuPA Open Proteomics
Volume11
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Amyloidosis
Proteomics
Amyloid
Biomarkers
Mass spectrometry
Mass Spectrometry
Proteins
Tissue

Keywords

  • Amyloidogenic proteins
  • Amyloidosis
  • Clinical proteomics
  • Proteotoxicity
  • Tissue biomarkers

ASJC Scopus subject areas

  • Biochemistry

Cite this

Systemic amyloidoses and proteomics : The state of the art. / Lavatelli, Francesca; di Fonzo, Andrea; Palladini, Giovanni; Merlini, Giampaolo.

In: EuPA Open Proteomics, Vol. 11, 01.06.2016, p. 4-10.

Research output: Contribution to journalArticle

@article{2e81a334d026428190d0189a4107b5db,
title = "Systemic amyloidoses and proteomics: The state of the art",
abstract = "Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.",
keywords = "Amyloidogenic proteins, Amyloidosis, Clinical proteomics, Proteotoxicity, Tissue biomarkers",
author = "Francesca Lavatelli and {di Fonzo}, Andrea and Giovanni Palladini and Giampaolo Merlini",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.euprot.2016.02.003",
language = "English",
volume = "11",
pages = "4--10",
journal = "EuPA Open Proteomics",
issn = "2212-9685",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Systemic amyloidoses and proteomics

T2 - The state of the art

AU - Lavatelli, Francesca

AU - di Fonzo, Andrea

AU - Palladini, Giovanni

AU - Merlini, Giampaolo

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

AB - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

KW - Amyloidogenic proteins

KW - Amyloidosis

KW - Clinical proteomics

KW - Proteotoxicity

KW - Tissue biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84959345894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959345894&partnerID=8YFLogxK

U2 - 10.1016/j.euprot.2016.02.003

DO - 10.1016/j.euprot.2016.02.003

M3 - Article

AN - SCOPUS:84959345894

VL - 11

SP - 4

EP - 10

JO - EuPA Open Proteomics

JF - EuPA Open Proteomics

SN - 2212-9685

ER -